Novo Nordisk reports positive weekly growth hormone data
A phase III study has demonstrated that Sogroya, a weekly injection, works as well as daily drug Norditropin to treat children with growth hormone deficiency.
by marketwire, translated by daniel pedersen
Novo Nordisk has presented positive results from a phase III trial of its treatment for children with growth hormone deficiency, dubbed Sogroya, according to a company press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
General Manager of Novo Nordisk in Denmark to move to Japan
For subscribers
FDA rejects Pfizer's weekly growth hormone
For subscribers
.jpg)
.jpg&w=384&q=75)
